Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kangbingdu granules for hospitalized adults with mild COVID-19 pneumonia
ChiCTR2000029781Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Kangbingdu Granules in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Union Hospital. Primary endpoint: Disappearance rate of fever symptoms. Started Feb 2020; status: recruiting.
02
Drugs
Kangbingdu Granules
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on ChiCTR2000029781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029781.